By: Yurong Zhang, Haiyan Zhang, Huirong Shan, Yuyang Qi, Yanyan Feng, Sumei Wang, Li Xu, Wei Wei, Shoudong Zhang, Sha Chen, Xiaohui Dai
Keywords: Adverse event; eltrombopag; rituximab; immune thrombocytopenic purpura; efficacy.
DOI : 10.36721/PJPS.2025.38.5.REG.14225.1
Abstract: This study aimed to evaluate the efficacy and safety of eltrombopag plus rituximab in the treatment of patients with immune thrombocytopenic purpura (ITP). Sixty ITP patients treated from September 2022 to September 2023 were recruited for this study, and were randomly divided into a control group and a treatment group. The former was given eltrombopag, and the later was given eltrombopag plus rituximab. The treatment efficacy, platelet levels, coagulation function, sustained effective SR, progression-free-survival, and incidence of adverse reactions and adverse events were compared in both groups using SPSS 22.0 statistical software. After nine months of treatment, the platelet level of the treatment group was significantly better than that of the control group (P<0.05). The platelet levels of the treatment group were better than those of the control group at discharge and 6 months after discharge (P<0.05). After treatment, the levels of PT and APPT in the treatment group were lower than those in the control group (P<0.05). There was no difference in the incidence of adverse reactions and adverse events between 2 groups after treatment (P>0.05). In conclusion, eltrombopag combined with rituximab can effectively improve the efficacy of treatment in ITP patients, with high safety.
[View Complete Article]
